Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache

RECOMMENDED

Migraine and Headache

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

★ 3 Recommended by Prof. Dr Christian Kamm, Faculty Member

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Cephalalgia.

Dodick DW, Goadsby PJ, Lucas C, Jensen R, Bardos JN, Martinez JM, Zhou C, Aurora SK, Yang JY, Conley RR, Oakes T

doi: 10.1177/0333102420905321.

RECOMMENDED

Migraine and Headache

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache

Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, Pearlman EM

doi: 10.1111/head.13970

RECOMMENDED

Migraine and Headache

Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II

★ 2 Recommended by Prof. Dr Christian Kamm, Faculty Member

★ 3 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN

doi: 10.1111/head.13766.

Migraine and Headache

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

Headache

Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD

doi: 10.1111/head.14138

Migraine and Headache

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

BMC Neurol.

Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL

doi: 10.1186/s12883-018-1193-2.

Migraine and Headache

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Headache

Lipton RB, Cohen JM, Bibeau K, Galic M, Seminerio MJ, Ramirez Campos V, Halker Singh RB, Ailani J

doi: 10.1111/head.13997

Migraine and Headache

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

Headache.

Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C

doi: 10.1111/head.13636.

Migraine and Headache

Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine

Cephalalgia

Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J, Dong Y, Pearlman EM

doi: 10.1177/0333102420966658

RECOMMENDED

Migraine and Headache

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache

Ford JH, Kurth T, Starling AJ, Ayer DW, Wietecha LA, Port MD, Rettiganti M, Ruff DD

doi: 10.1111/head.14013

Related content

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies

Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies

Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine